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Nuclear receptor co-activators and HER-2/neu are upregulated in
breast cancer patients during neo-adjuvant treatment with
aromatase inhibitors
M Hauglid Fla˚geng1,2, LL Haugan Moi1,3, JM Dixon4, J Geisler5,6, EA Lien1,2, WR Miller4, PE Lønning1,7 and
G Mellgren*,1,2
1Institute of Medicine, University of Bergen, N-5021 Bergen, Norway; 2The Hormone Laboratory, Haukeland University Hospital, N-5021 Bergen,
Norway; 3Section of Endocrinology, Division of Medicine, University Hospital of North Norway, N-9038 Tromsø, Norway; 4Edinburgh Breast Unit, Western
General Hospital, University of Edinburgh, Edinburgh EH4 2XU, UK; 5Faculty Division at Akershus University Hospital, University of Oslo, N-1478
Lørenskog, Norway; 6Department of Medicine, Section of Oncology, Akershus University Hospital, N-1478 Lørenskog, Norway; 7Department of Oncology,
Haukeland University Hospital, N-5021 Bergen, Norway
BACKGROUND: Acquired resistance to endocrine therapy in breast cancer is poorly understood. Characterisation of the molecular
response to aromatase inhibitors in breast cancer tissue may provide important information regarding development of oestrogen
hypersensitivity.
METHODS: We examined the expression levels of nuclear receptor co-regulators, the orphan nuclear receptor liver receptor
homologue-1 and HER-2/neu growth factor receptor using real-time RT-PCR before and after 13–16 weeks of primary medical
treatment with the aromatase inhibitors anastrozole or letrozole.
RESULTS: mRNA expression of the steroid receptor co-activator 1 (SRC-1) and peroxisome-proliferator-activated receptor g
co-activator-1a (PGC-1a) was correlated (P¼ 0.002), and both co-activators increased during treatment in the patient group as a
whole (P¼ 0.008 and P¼ 0.032, respectively), as well as in the subgroup of patients achieving an objective treatment response
(P¼ 0.002 and P¼ 0.006). Although we recorded no significant change in SRC-3/amplified in breast cancer 1 level, the expression
correlated positively to the change of SRC-1 (P¼ 0.002). Notably, we recorded an increase in HER-2/neu levels during therapy in the
total patient group (18 out of 26; P¼ 0.016), but in particular among responders (15 out of 21; P¼ 0.008).
CONCLUSION: Our results show an upregulation of co-activator mRNA and HER-2/neu during treatment with aromatase inhibitors.
These mechanisms may represent an early adaption of the breast cancer cells to oestrogen deprivation in vivo.
British Journal of Cancer (2009) 101, 1253–1260. doi:10.1038/sj.bjc.6605324 www.bjcancer.com
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Hormonal manipulations through oestrogen deprivation or
administration of anti-oestrogens have a key function in breast
cancer therapy. The third-generation aromatase inhibitors (AIs)
have shown improved outcome compared to tamoxifen when used
as adjuvant therapy and in treatment of metastatic disease in
postmenopausal women (Bonneterre et al, 2001; Mouridsen et al,
2001; Howell et al, 2005; Jakesz et al, 2005; Thurlimann et al, 2005;
Coombes et al, 2007). However, although first-line hormonal
therapy may cause an objective response among 20–50% of
patients with metastatic breast cancer and stabilise disease in many
patients (Bonneterre et al, 2001; Mouridsen et al, 2001), resistance
and disease progression inevitably occur.
Patients receiving neo-adjuvant treatment with the AIs experi-
ence a profound suppression of oestrogen levels, and the
suppression of oestrogen in tumour is comparable with the fall
in plasma oestrogen levels and in vivo total body aromatase
inhibition (Geisler et al, 2001, 2002, 2008). In vitro models of de
novo resistance to endocrine therapy have indicated that breast
cancer cells have the ability to adapt to low oestrogen levels by
developing oestrogen hypersensitivity (Lippman et al, 1976;
Masamura et al, 1995; Chan et al, 2002) through changes in gene
expression and activation of growth factor pathways (Kuang et al,
2005; Santen et al, 2005). Thus, characterisation of the molecular
response to AIs in breast cancer tissue may provide important
information regarding development of oestrogen hypersensitivity.
The transcriptional activity of the oestrogen receptor (ER) is
regulated not only by its ligands, but also by the levels of ER co-
regulators. High levels of co-activators may force ER into an active
conformation that stimulates oestrogen-induced gene expression
(Jordan and O’Malley, 2007). Thus, changes in the levels of ER
co-activators may be of importance for the response to endocrine
therapy. The expression of the steroid receptor co-activator-1
(SRC-1) has been associated with nodal positivity and endocrine
resistance (Fleming et al, 2004; Myers et al, 2004). Furthermore,
SRC-3/AIB1 is over-expressed in more than 30% of breast cancers
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with gene amplification in 5–10% of the tumours (Anzick et al,
1997; Murphy et al, 2000; List et al, 2001). Growth factor pathways
may activate the co-activators at the posttranscriptional level
(Rowan et al, 2000; Fleming et al, 2004; Wu et al, 2007; O’Malley
et al, 2008), and over-expression of these co-activators, similar to
over-expression of HER-2/neu, has been associated with inferior
response to endocrine therapy (Osborne et al, 2003; Shin et al,
2006). It has been reported that status of some patients converts
from HER-2/neu negative at the initiation of endocrine therapy to
positive serum HER-2/neu at the time of progression (Lipton et al,
2005). However, the knowledge of HER-2/neu expression and the
levels of ER co-regulators in tumour tissue during treatment with
AIs is limited.
The orphan nuclear receptor liver receptor homologue-1 (LRH-1)
is a specific activator of aromatase gene expression in human
breast pre-adipocytes and a regulator of oestrogen biosynthesis
(Clyne et al, 2002; Zhou et al, 2005). Although LRH-1
is transcriptionally regulated by ER (Annicotte et al, 2005) and is
stimulated by co-activators, such as the peroxisome-proliferator-
activated receptor g co-activator-1a (PGC-1a), to execute its
function (Safi et al, 2005), little is known about the regulation of
LRH-1 and PGC-1a in breast tumour tissue during aromatase
inhibition.
Although several studies have reported the different NR
co-regulators to be over-expressed in breast cancer (Anzick et al,
1997; Bautista et al, 1998; Berns et al, 1998; Bouras et al, 2001; List
et al, 2001; Hudelist et al, 2003; Iwase et al, 2003; Osborne et al,
2003; Fleming et al, 2004; Myers et al, 2004, 2005), little is known
about the levels of co-regulators during oestrogen deprivation
through treatment with AIs. Of interest, the level of the ER co-
repressor NCoR has been shown to be downregulated in breast
cancer cells resistant to anti-oestrogens (Wang et al, 2006). In this
study, we examined the mRNA levels of the ER co-regulators
SRC-1, SRC-3/AIB1, PGC-1a, NCoR, the nuclear receptor LRH-1 as
well as the HER-2/neu growth factor receptor, together with other
potential markers of endocrine response (pS2 and Ki67) and tissue
oestrogen levels from the same tumours before and during
treatment with the third-generation AIs anastrozole and letrozole.
MATERIALS AND METHODS
Study population
This material was collected in three similar protocols performed in
Bergen, Norway (B) and Edinburgh, UK (E) as previously reported
(Geisler et al, 2001, 2008; Miller et al, 2006). In summary, a total
of 31 breast cancer patients treated with a non-steroidal AI
(anastrozole or letrozole) as primary medical treatment (pre-
viously termed neo-adjuvant therapy) were enrolled. All patients
provided written informed consent, and each protocol was
approved by the local regulatory authorities.
Treatment and tissue collection
Of 31 patients, 12 received anastrozole as an oral dose of 1mg daily
for 15 weeks (B), whereas letrozole was given as an oral dose of
2.5mg daily with a treatment period of 16 weeks for 12 patients (B)
and 13 weeks for 7 patients (E). Treatment was administered up to
the day of surgery.
Tumour size was estimated by calculating the product of the
largest diameter and its perpendicular. The patients were classified
as responders or non-responders depending on more or less than
50% reduction in tumour size, respectively. In two of the studies
(Geisler et al, 2001, 2008) clinical response was assessed by clinical
tumour measurement using a calliper. In the third study (Miller
et al, 2006) tumour assessment was carried out by ultrasound.
Breast tumour tissue available for gene expression analysis was
collected by core-cut (E) or incisional biopsy (B) before treatment
and during final surgery.
Tissue oestrogen measurements and histochemical
methods
Intra-tumoural levels of E1, E2 and E1S were measured in the
Norwegian materials using a highly sensitive HPLC-RIA method
(Geisler et al, 2000), and are previously reported (Geisler et al,
2001, 2008).
ER, progesterone receptor (PR), HER-2/neu, Ki67 and the
oestrogen-regulated gene pS2 were analysed using standard
immunohistochemical methods as already published (Geisler
et al, 2001; Miller et al, 2006). ER and PR were reported as
percentage of positively stained cells and the tumours were
considered positive if X10% of the cells stained for ER/PR (B), or
as Allred score (E) where the first number represents an estimation
of ER- or PR-positive tumour cells (0, none; 1,o1%; 2, 1–10%; 3,
10–33%; 4, 33–66% and 5, 466%) and the second number
represents the average intensity of ER- or PR-positive tumours
cells (0, none; 1, weak; 2, intermediate and 3, strong) (Harvey et al,
1999). Apoptosis was estimated using the TUNEL method
(terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick
end labelling).
Quantitative real-time RT-PCR
Tumour tissue was homogenised using a MagNA Lyser (50–
100mg; Roche, Basel, Switzerland) or manually (B25mg) and
total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s recommendations. Total
RNA was resuspended in PCR-grade water, and RNA quality and
concentration were estimated by optical density measurement
using the Nanodrop (Saveen Werner, Copenhagen, Denmark) and
a Bioanalyzer (Applied Biosystems, Lincoln, CA, USA). Each
sample of 1 mg total RNA was reverse transcribed using the First
Strand cDNA Synthesis Kit (Roche). The cDNA was stored at
201C until use.
Real-time PCR reactions were carried out on a LightCycler 3
(Roche) using the SYBR Green detection format. Because of a
marked variation in expression levels of our target genes, we
calculated the expression relative to the geometric mean of two
housekeeping genes: glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), which demonstrated a considerable higher mRNA-
expression profile compared to the other reference gene, TATA-
box binding protein (TBP). After each PCR run, a melting curve
analysis was carried out to control for production of primer dimers
and/or unwanted PCR products. An RNA standard was also
included in every PCR run to control for inter-assay variation.
Gene specific primers from Eurogentec (Herstal, Belgium) and TIB
Molbiol (Berlin, Germany) were: SRC-1 (sense, 50-aggcccagagccagt
ttac-30; anti-sense, 50-caggatctccgatttgatggtta-30), SRC-3/AIB1
(sense, 50-gaccgcttttacttcaggcatt-30; anti-sense, 50-tgtgttaaccaggtcc
tcttgct-30), PGC-1a (sense, 50-cccatttgagaacaagactat-30; anti-sense,
50-ggttatcttggttggcttt-30), NCoR (sense, 50-gatctatactcgtctcatctccgt-30;
anti-sense, 50-agcaggctgaaggacttcc-30), LRH-1 (sense, 50-gctctccagc
aagcatcc-30; anti-sense, 50-tcatttggtcatcaaccttaa-30), HER-2/neu
(sense, 50-ccagccttcgacaacctctatt-30; anti-sense, 50-tgccgtaggtgtccct
ttg-30), GAPDH (sense, 50-accacagtccatgccatcac-30; anti-sense, 50-tc
caccaccctgttgctgta-30) and TBP (sense, 50-tgcacaggagccaagagtgaa-30;
anti-sense, 50-cacatcacagctccccacca-30).
Expression levels of mRNA were estimated using external
standard curves with serially diluted plasmids with known
concentration for each target gene, except for HER-2/neu where
serially diluted cDNA from an HER-2/neu-positive patient sample
were used. Fold change in mRNA expression during treatment
was calculated using the crossing point (Cp) for each sample
and the efficiency (Eff) of each transcript, using the formula
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Efftarget gene
DCp/Effhousekeeping gene
DCp. The fold change was estima-
ted relative to both GAPDH and TBP, and thereafter calculated as
the geometric mean of both (Pfaffl, 2001).
Statistical analysis
The relative values of mRNA expression for all genes analysed and
tissue oestrogen levels were found to be log-normally distributed.
Thus, all values are presented as their geometric mean with 95%
confidence intervals. Comparison between response groups was
carried out using the Mann–Whitney U-test. Changes in gene
expression during treatment were analysed using Wilcoxon signed
rank test, and correlation between parameters was analysed using the
Spearman rank correlation coefficient. The Ki67, pS2 and percentage
of apoptotic cells are given as their arithmetic means. To reduce the
number of false positives, we set the threshold P-value for statistical
significance to 0.01. All statistical analyses were carried out using
SPSS software package, version 14.0.2 (SPSS, Chicago, IL, USA).
RESULTS
A total of 31 patients were treated with anastrozole or letrozole as
primary medical therapy for 13–16 weeks before surgery. One
patient was excluded because of insufficient quantities of tissue
available, leaving 30 tumour samples for gene expression analysis.
Only ER-positive breast cancers were eligible for the study, but
one tumour turned out to be ER negative at re-analysis with
immunohistochemistry. The same tumour was the only HER-2/
neu-amplified tumour in the study and was one out of six tumours
that did not respond to therapy. Clinical data and tumour
characteristics are summarised in Table 1.
The mRNA expression levels of the co-activators SRC-1, SRC-3/
AIB1, PGC-1a, co-repressor NCoR, the orphan nuclear receptor
LRH-1 and the HER-2/neu growth factor receptor were examined
in human breast cancer tissue before and during aromatase
inhibition. Noteworthy, we did not observe any significant
differences in mRNA expression between anastrozole- and
letrozole-treated subjects or between the subgroups treated with
letrozole for 13 and 16 weeks. Analysing all patients together, the
mRNA levels of our target genes were as presented in Table 2.
We observed no correlations among pre-treatment mRNA levels
of the co-activators SRC-1, SRC-3/AIB1, co-repressor NCoR and
the orphan nuclear receptor LRH-1. However, PGC-1a mRNA
expression pre-treatment level correlated to change in Ki67
expression.
During treatment, the mRNA levels of SRC-1 were upregulated
in 22 of 30 subjects (Figure 1A) with a mean fold change of 1.40
(P¼ 0.008). A non-significant increase in SRC-3/AIB1 mRNA
expression was also observed (mean change of 1.32; P¼ 0.090).
PGC-1a mRNA increased in 21 out of 27 tumours expressing
detectable levels at baseline, but the observed change in the total
patient group was not statistical significant (Figure 1B; mean
change of 1.91; P¼ 0.032). No significant change in expression of
NCoR or LRH-1 was detected. HER-2/neu mRNA was upregulated
in 18 out of 26 tumours (Figure 1C) with a mean fold change of
1.35 (borderline significance; P¼ 0.016). The overall fold changes
in SRC-1 mRNA expression correlated positively to expression of
PGC-1a (R¼ 0.565, P¼ 0.002) as well as SRC-3/AIB1 (R¼ 0.551,
P¼ 0.002).
Among responders, SRC-1 was upregulated in 20 out of 24
tumours (Figure 1A, mean change of 1.62; P¼ 0.002). This change
during treatment appeared to be different compared to the
mean change of 0.79 among six non-responders (P¼ 0.023).
Table 1 Treatment and tumour characteristics for the patients
Patient Treatment Hospital Treatment period ERa PRa Responseb HER-2/neu
1 Letrozole Bc 16 100 30/40 R Neg.
2 Letrozole B 16 450 450 R Neg.
3 Letrozole B 16 70/80 10 R Neg.
4 Letrozole B 16 80 o10 R NA
5 Letrozole B 16 100 100 R Neg.
6 Letrozole B 16 100 100 R Neg.
7 Letrozole B 16 100 100 R Neg.
8 Letrozole B 16 450 450 R Neg.
9 Letrozole B 16 100 100 R Neg.
10 Letrozole B 16 100 50 R Neg.
11 Letrozole B 16 80/100 0/20 R Neg.
12 Letrozole B 16 480 480 R Neg.
13 Letrozole E 13 5+3 1+2 R NA
14 Letrozole E 13 5+3 4+2 R NA
15 Letrozole E 13 5+3 3+3 R NA
16 Letrozole E 13 5+2 5+2 R NA
17 Anastrozole B 15 86 53 R Neg.
18 Anastrozole B 15 93 0 R Neg.
19 Anastrozole B 15 83 84 R Neg.
20 Letrozole E 13 5+3 5+3 R NA
21 Letrozole E 13 5+3 5+3 R NA
22 Anastrozole B 15 98 0 R Neg.
23 Anastrozole B 15 92 86 R Neg.
24 Anastrozole B 15 87 70 R Neg.
25 Letrozole E 13 5+3 5+3 NR NA
26 Anastrozole B 15 92 79 NR Neg.
27 Anastrozole B 15 NA NA NR Neg.
28 Anastrozole B 15 91 86 NR Neg.
29 Anastrozole B 15 2 0 NR Pos.
30 Anastrozole B 15 82 7.5 NR Neg.
Abbreviations: NA¼ not available; Neg.¼ negative; Pos.¼ positive; R¼ responders; NR¼ non-responders. aExpressed as percentage of cells staining positively (IHC) or as an
Allred score (Harvey et al, 1999). bClassification of treatment response was based on change in tumour size calculated as a product of the largest diameter and its perpendicular
and subjects presented as R or NR. cPatients were treated at Haukeland University Hospital, Bergen (B) or Edinburgh Breast Unit Western General Hospital (E).
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Pre-treatment levels of PGC-1a mRNA were higher in tumours not
responding compared to those responding to therapy (borderline
significance; P¼ 0.012). Notably, PGC-1a mRNA was upregulated
in 19 out of 21 responders (mean change of 2.75; P¼ 0.006). This
increase was significantly different from the mean change of 0.54
in non-responders (P¼ 0.002). HER-2/neu mRNA was upregulated
in 15 out of 21 responders that were available for analysis
(Figure 1C) with a significant mean fold change of 1.66 (P¼ 0.008).
This increase in responders appeared to be different compared to
the mean change of 0.58 among non-responders (P¼ 0.186).
However, as for changes in mRNA expression of SRC-1, SRC-3/
AIB1, NCoR and LRH-1, the difference between responders and
non-responders was not significant (Figure 2).
Intra-tumoural concentrations of E1, E2 and E1S and bio-
markers, including Ki67, pS2 and apoptotic cells, are presented in
Table 3. As expected, PR, pS2 and Ki67 decreased significantly
during treatment in both responders and non-responders, with a
more profound decrease of Ki67 among responders. Except for a
non-significant positive correlation between SRC-1 and LRH-1
mRNA expression and the expression of Ki67 during treatment
(R¼0.502, R¼0.648 and P¼ 0.040, P¼ 0.017, respectively), no
correlation between changes in mRNA levels and expression of
pS2, Ki67 or degree of oestrogen suppression was recorded (data
not shown).
DISCUSSION
Changes in gene expression profiles in breast cancer tumours
during endocrine treatment have been reported before (Kristensen
et al, 2005; Mackay et al, 2007; Miller et al, 2007, 2009; Harvell
et al, 2008). To our knowledge this is the first study evaluating
expression of nuclear receptor co-regulators in breast cancer
patients during oestrogen deprivation. The ER co-activators SRC-1
and SRC-3/AIB1 have been previously linked to endocrine
sensitivity in breast cancer. High levels of SRC-1 and/or SRC-3/
AIB1 are suggested to be associated with insensitivity to treatment
with tamoxifen (Myers et al, 2004), and HER-2/neu over-
expression confers an inferior response to treatment with
tamoxifen as well as to AIs (Shin et al, 2006; Dowsett et al, 2008;
Rasmussen et al, 2008).
We observed a significant increase in SRC-1 and PGC-1a mRNA
expression in response to treatment with two third-generation
non-steroidal AIs. SRC-1 and PGC-1a enhance ER activity, and
increased levels may sensitise cells to oestrogens at lower
concentrations (Lonard et al, 2007).
Several groups have reported MCF-7 cells exposed to E2 at low
concentrations over time to develop a state of hypersensitivity,
achieving growth stimulation at a hormone concentration 1 out of
1000 to 1 out of 10 000 the concentration required for wild-type
cells (Lippman et al, 1976; Masamura et al, 1995; Martin et al,
2003). Although several mechanisms, including activation of the
insulin-like growth factor receptor and mitogen-activated protein
kinases, have been provided (Santen et al, 2005; Sabnis et al, 2007),
some data indicate HER-2/neu may be important (Song et al, 2002;
Martin et al, 2003, 2005). Still we lack scientific evidence showing
that such mechanisms actually occur in vivo and can be related to
therapy resistance. Although our data should be interpreted with
care, to our knowledge they represent the first evidence of
mechanisms that could possibly sensitise tumour cells to oestrogen
stimulation in response to aromatase inhibition in vivo. The
upregulation of co-activators and HER-2/neu was evident in
Table 2 Influence of anastrozole and letrozole on SRC-1, SRC-3/AIB1, PGC-1a, NCoR, LRH-1 and HER-2/neu mRNA expression
Pre-treatment On treatment Fold change P for changea P between subgroupsb
SRC-1
All patients 0.2961 (0.2059–0.4260)c 0.4034 (0.2583–0.6301)d 1.40 (1.11–1.79) 0.008 0.023
Responders 0.3576 (0.2496–0.5123) 0.5585 (0.3888–0.8023) 1.62 (1.29–2.04) 0.002
Non-responders 0.1391 (0.0419–0.4622) 0.1098 (0.0220–0.5484) 0.79 (0.38–1.65) 0.463
SRC-3/AIB1
All patients 0.3682 (0.3053–0.4440) 0.4367 (0.3562–0.5354) 1.32 (1.08–1.62) 0.090 0.667
Responders 0.3482 (0.2832–0.4281) 0.4223 (0.3344–0.5334) 1.21 (0.97–1.52) 0.078
Non-responders 0.4562 (0.2606–0.7985) 0.4969 (0.2803–0.8810) 1.09 (0.56–2.10) 0.753
PGC-1a
All patients 0.0023 (0.0014–0.0037)e 0.0040 (0.0027–0.0058) 1.91 (1.20–3.05) 0.032 0.002
Responders 0.0017 (0.0011–0.0027) 0.0041 (0.0028–0.0061) 2.75 (1.74–4.34) 0.006
Non-responders 0.0072 (0.0021–0.0245) 0.0037 (0.0009–0.0150) 0.54 (0.22–1.31) 0.116
NCoR
All patients 0.2028 (0.1447–0.2842) 0.2342 (0.1756–0.2842) 1.16 (0.92–1.46) 0.245 0.437
Responders 0.1897 (0.1264–0.2848) 0.2280 (0.1609–0.3231) 1.20 (0.93–1.56) 0.162
Non-responders 0.2651 (0.1398–0.5026) 0.2607 (0.1465–0.4639) 0.98 (0.47–2.05) 0.753
LRH-1
All patients 0.0127 (0.0082–0.0196) 0.0167 (0.0129–0.0216) 1.31 (0.87–1.98) 0.074 0.227
Responders 0.0117 (0.0067–0.0205) 0.0162 (0.0120–0.0219) 1.39 (0.81–2.38) 0.091
Non-responders 0.0169 (0.0093–0.0307) 0.0184 (0.0088–0.0383) 1.09 (0.62–1.90) 0.753
HER-2/neu
All patients 0.5388 (0.3780–0.7681) 0.8288 (0.5213–1.3180) 1.35 (0.94–1.94) 0.016 0.186
Responders 0.4777 (0.3525–0.6525) 0.8659 (0.5721–1.3106) 1.66 (1.27–2.18) 0.008
Non-responders 1.6320 (0.4482–5.9430) 0.9298 (0.0702–12.3108) 0.58 (0.08–4.13) 0.893
aPre-treatment levels were compared to on-treatment levels after 13–16 weeks using the Wilcoxon 2 group test. bComparisons of mRNA-levels between responders and non-
responders during treatment were performed using the Mann–Whitney U-test. cAll the relative values are given as geometric means with 95% confidence intervals. dExclusively
for SRC-1, on-treatment levels are significant different between response groups P¼ 0.009 (Mann–Whitey U-test). eExclusively for PGC-1a, pre-treatment levels are in
borderline significant different between response groups, P¼ 0.012 (Mann–Whitey U-test).
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treatment responsive tumours in contrast to no significant changes
in the subgroup of non-responsive tumours. Our observations may
suggest activation of regulatory mechanisms in response to E2
suppression in endocrine-sensitive cells that are absent or less
active in tumours insensitive to hormonal manipulation. Thus, one
possible hypothesis is that the increasing levels of SRC-1 and
PGC-1a represent a cellular response to AIs and that the increase
in co-activator levels may reflect the efficiency of endocrine
therapy. At the same time, changes in gene expression that could
Fo
ld
 c
ha
ng
e 
in
 H
ER
-2
/n
eu
 e
xp
re
ss
io
n
10
Responders
* * * *
Responders
Responders
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Patients
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Patients
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Patients
1
0.1
Fo
ld
 c
ha
ng
e 
in
 P
G
C-
1
 
ex
pr
es
sio
n
10
1
0.1
Fo
ld
 c
ha
ng
e 
in
 S
RC
-1
 e
xp
re
ss
io
n
10
1
0.1
N
D
N
D
N
D
Non-responders
Non-responders
Non-responders
Figure 1 Individual fold changes in mRNA expression of SRC-1 (A),
PGC-1a (B) and HER-2/neu (C) in patients during oestrogen deprivation.
RNA was purified from the same breast tumour in the individual breast
cancer patient before and after 13–16 weeks of treatment with either
letrozole or anastrozole. Fold change in mRNA expression was estimated
using real-time RT-PCR and presented relative to the housekeeping genes
GAPDH and TBP. Calculations are based on the crossing point (Cp) for each
sample and the efficiency (Eff) of each transcript, using the formula Efftarget
gene
DCp/Effhousekeeping gene
DCp. Patients marked as not detected (n.d.) had
Cp outside the detection limit. Patients marked by * are excluded due to
insufficient tumour tissue left for analysis.
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Figure 2 Fold change in mRNA expression of target genes during
oestrogen deprivation. RNA was purified from tumours from breast cancer
patients before and after 13–16 weeks of treatment with either letrozole
or anastrozole. Patients were classified as responders (R) or non-
responders (NR) based on clinical tumour measurements during treatment.
SRC-1 (R, n¼ 24; NR, n¼ 6), SRC-3/AIB1 (R, n¼ 23; NR, n¼ 6), PGC-1a
(R, n¼ 21; NR, n¼ 6), NCoR (R, n¼ 24; NR, n¼ 6), LRH-1 (R, n¼ 19; NR,
n¼ 6) and HER-2/neu (R, n¼ 21; NR, n¼ 5) mRNA expression was
estimated using real-time RT-PCR. Fold change in mRNA expression during
treatment was calculated using the crossing point (Cp) for each sample and
the efficiency (Eff) of each transcript, using the formula Efftarget gene
DCp/
Effhousekeeping gene
DCp. The fold changes are presented as geometric mean
with 95% confidence interval of the fold change calculated relative to the
housekeeping genes GAPDH and TBP. Differences in fold changes between
R and NR were analysed by the Mann–Whitney U-test: SRC-1; P¼ 0.023,
SRC-3/AIB1; P¼ 0.667, PGC-1a; P¼ 0.002, NCoR; P¼ 0.437, LRH-1;
P¼ 0.227 and HER-2/neu; P¼ 0.186.
Table 3 Change in biomarker and oestrogen levels during treatment
with AIs
Pre-treatment On treatmenta (%)
E1
b 208.6 12.1
E2
b 311.5 4.9
E1S
b 112.3 15.4
Ki67c 17.0 34.1
pS2c 45.3 28.0
Apoptotic cellsc 1.7 64.7
aOn treatment levels are presented as percentage of pre-treatment levels. bIntra-
tumoural levels of E1, E2 and E1S (fmol/g) measured by an HPLC-RIA method and
given as geometric means. cKi67 and pS2 measured by immunohistochemistry and
percentage of apoptotic cells analysed by the TUNEL method and results given as
their arithmetic means.
Co-activators, HER-2/neu and aromatase inhibitors
M Hauglid Fla˚geng et al
1257
British Journal of Cancer (2009) 101(8), 1253 – 1260& 2009 Cancer Research UK
C
li
n
ic
a
l
S
tu
d
ie
s
potentially lead to increased oestrogen sensitivity could be one of
several mechanisms contributing to acquired therapy resistance
evolving over time. However, because the non-responders
represent a small subgroup in this study, the data concerning
the subgroups should be interpreted with caution.
Even though the levels of PGC-1a for all patients were more
than a 100-fold lower compared to the other co-activators, pre-
treatment PGC-1a expression did most clearly separate between
the responding groups with a 4-fold higher geometric mean value
among non-responders compared to responders. PGC-1a is known
to interact with SRC-1 for full transcriptional activity (Puigserver
et al, 1999; Bourdoncle et al, 2005), and it is an important regulator
of LRH-1 and peroxisome-proliferator-activated receptor g
(Puigserver et al, 1999; Safi et al, 2005).
LRH-1 is suggested to exert oncogenic effects through effects on
aromatase expression and cell-cycle regulators such as G1-phase
cyclins (Clyne et al, 2002; Annicotte et al, 2005; Zhou et al, 2005).
We observed no changes of LRH-1 mRNA during treatment, which
would suggest that local aromatase upregulation by this transcrip-
tional activator may not be a response to oestrogen deprivation.
On the other hand, it is well known that the transcriptional
activity of LRH-1 is stimulated through interaction with the SRCs
(Xu et al, 2004). Thus, even though the LRH-1 mRNA expression is
unaffected during oestrogen deprivation, this does not rule out
that the transcriptional activity of LRH-1 is increased.
A significant increase in HER-2/neu expression was observed
during therapy among tumours responsive to AIs. The serum level
of HER-2/neu has been shown to be increased from baseline to
time of progression in approximately 25% of patients treated with
letrozole or tamoxifen (Lipton et al, 2005). In addition, in vitro
studies have shown that oestrogen deprivation is associated with
an increase in HER-2/neu expression (Dati et al, 1990; Read et al,
1990; Warri et al, 1991). Recently, it was reported that letrozole
upregulates the protein level of HER-2/neu in MCF-7Ca xenografts
in mice despite continued response to treatment, and it has been
hypothesised that an inverse relationship exists between HER-2/
neu and ERa (Sabnis et al, 2009). In line with this, it has been
shown that HER-2/neu transcription can be repressed by oestrogen
(Bates and Hurst, 1997). A recent report shows that the
transcription factor-paired box 2 gene product (PAX2) and
SRC-3/AIB1 compete for binding and regulation of HER-2/neu
transcription in MCF-7 cells (Hurtado et al, 2008). High levels of
SRC-3/AIB1 outcompete PAX2 leading to an increase in the HER-
2/neu transcription after tamoxifen treatment (Hurtado et al,
2008). SRC-3/AIB1 has also been shown to be required for HER-2/
neu oncogenic activity (Fereshteh et al, 2008). Even though we did
not observe a correlation between changes in SRC-3/AIB1 and
HER-2/neu mRNA expression in our study, the expression of both
genes increased during oestrogen deprivation. It is possible that
the enhanced level of HER-2/neu mRNA could be explained by loss
of repression due to an increase in SRC-3/AIB1 or other ER
co-activators. Interestingly, it has recently been reported that
patients with ER-positive and HER-2/neu-negative breast cancer
with a poor response to tamoxifen may obtain an increased time to
progression by having the tyrosine kinase inhibitor lapatinib
added to letrozole (Johnston et al, 2009). Thus, an increase in
HER-2/neu expression may represent a circumvention of oestro-
gen deprivation.
In this study we have focused on accurate quantifications of
mRNA expression, but it should be noted that changes in mRNA
and protein expression are not always similar, and one should
keep in mind that post-translational modifications and regulation
of protein turnover rates may also affect the co-regulator protein
levels (Greenbaum et al, 2003).
In conclusion, the results from this study with unique matched
pre- and on-treatment samples suggest that co-activators and
HER-2/neu are upregulated in tumours during AI therapy as an
early response to effective oestrogen deprivation. Increasing levels
of co-activator mRNA may represent a response by the cells to
antagonise the oestrogen deprivation effect of anastrozole and
letrozole.
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